1. Introduction {#sec0005}
===============

1.1. Origins of EAE: from primates to rodents {#sec0010}
---------------------------------------------

Trials to investigate pathogenetic, diagnostic and therapeutic aspects of multiple sclerosis (MS) in animal models date back to the first half of the 20th century ([@bib0910]) ([Fig. 1](#fig0005){ref-type="fig"} ). Before, Louis Pasteur\'s rabies vaccination ([@bib1295]) gave first hints to the possibility that immunization of humans with xenogenic nervous tissue induces ascending paralysis. Specifically, inoculation of rabies patients with desiccated spinal cord of rabies-infected rabbits caused pareses of limb, neck and facial muscles resulting in gait, swallowing and breathing problems ([@bib0080]). Conversely, it was shown by [@bib0830] and [@bib1585] that injection of human spinal cord or sheep brain into rabbits leads to limb paralysis (clumsy gait and muscle weakness). [@bib1420] first demonstrated in monkeys immunized with rabbit brain or brain extracts that paralysis was associated with perivascular infiltrates and demyelination in the brain and spinal cord. He called the disease acute disseminated encephalomyelitis, a term that was later changed to experimental allergic or autoimmune encephalomyelitis (EAE). Since the frequency and severity of paralyses was correlated to the titer of anti-brain antibodies, researchers in subsequent trials boosted the humoral immune response with Freund\'s adjuvant (CFA) ([@bib0430]), later complemented by pertussis toxin ([@bib1185]). Thereby they could induce oscillatory symptoms and relapsing--remitting courses of the disease accompanied by perivascular leukocyte infiltration in acute lesions and gliosis in chronic lesions both reminiscent of MS pathology ([@bib1705]). Experiments were performed first in guinea pigs ([@bib0435]) and monkeys ([@bib0735], [@bib1175], [@bib1705]) and later in various other species including mice ([@bib1245]) and rats ([@bib0955]) enabling more extensive immunogenetic, histopathological and therapeutic studies. It turned out that the histopathology and the clinical course of the disease varied significantly reflecting in part the heterogeneity of its human counterpart dependent on the genetic background of the animals, the source of the antigenic material and the mode of application of the antigen ([@bib0555], [@bib1250], [@bib1690]).Fig. 1Timeline of milestones in the history of animal models of MS. *Abbreviations*: AT-EAE, adoptive transfer EAE; CD, cluster of differentiation; CNS, central nervous system; MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein; TCR, T cell receptor; [@bib1795], [@bib0665] T helper cell.

1.2. Different types of EAE {#sec0015}
---------------------------

Importantly, by stepwise reduction of the complexity of the antigenic material from crude brain tissue and protein extracts through various central myelin proteins such as(i)myelin basic protein (MBP) ([@bib0340], [@bib0855]),(ii)myelin oligodendrocyte (ODC) glycoprotein (MOG) ([@bib0890]),(iii)proteolipid protein (PLP) ([@bib1630]),(iv)myelin-associated oligodendrocytic basic protein and 2′,3′-cyclic nucleotide 3′-phosphodiesterase ([@bib1045])

to small encephalitogenic peptides ([@bib0380], [@bib0900]) such as MBP~1--37~, MBP~1--11~, MBP~1--9~, MBP~83--99~, MOG~55--75~ and PLP~139--151~, more reproducible EAE models became available that mirror different features of MS ([@bib1690]). More recently a variety of additional antigens have been supposed to be involved in autoimmune reaction in MS and EAE ([Table 1](#tbl0005){ref-type="table"} ). Some of them are myelin constituents such as neurofascin NF 155 ([@bib1060]), others are expressed on myelin and axons such as contactin-2/transient axonal glycoprotein-1 (TAG-1) ([@bib0295]) and some are entirely non-myelin antigens such as the neuronal membrane protein neurofascin NF 186 ([@bib1060]), the neuronal cytoskeletal protein neurofilament-M ([@bib0850]) and the astrocyte-typical Ca^2+^-binding protein S100β ([@bib0825]). The neurofascins NF 155 and NF 186 and the adhesion molecule contactin-2/TAG-1have been identified as putative MS auto-antigens by a proteomics-based screening approach of MS sera and were subsequently shown to promote the autoimmune pathogenesis of EAE in rat models ([@bib0295], [@bib0300], [@bib1060]). Antibodies to neurofascins, in particular to NF 186, caused axonal injury without enhancing inflammation and demyelination in MOG--EAE ([@bib1060]). In contrast to MOG--EAE, contactin-2/TAG-1-specific T cells induced inflammatory lesions preferentially in the cerebral cortex and the spinal cord white and gray matter ([@bib0295]). However, while these cells were unable to cause demyelination by themselves they opened the blood--brain barrier (BBB) thereby allowing access of anti-MOG antibodies to the central nervous system (CNS) where they could trigger demyelination. The EAE variants induced by axonal antigens may reflect special features of MS subtypes, e.g. those characterized by cortical lesions or by histological patterns II and IV according to the classification of [@bib0990]. The schematic drawing in [Fig. 2](#fig0010){ref-type="fig"} indicates the molecular localisation of currently known putative auto-antigens in EAE. Proteins, glycoproteins and lipoproteins possessing encephalitogenic epitopes may be exposed to the outer surface of ODCs (1) or myelin (2) or they may reside in the compact myelin zone (3), at the myelin--axon interface (4) or the node of Ranvier (5). As to the last localisation the three adhesion molecules NF 155 and NF 186 contactin-2/TAG-1 are differentially expressed. Whereas NF 155 is localised at the paranodal myelin loop and interact with contactin-1/F3 and the contactin-associated protein 2 (caspr 2) on the axoplasm in a ternary complex ([@bib0225]), NF 186 is exposed in the non-myelinated part of the node of Ranvier and interacts with the neuron-glia-related cell adhesion molecule (NrCAM) and voltage-gated Na^+^ channels ([@bib0590]). Contactin-2/TAG-1 is also expressed juxtaparanodal by both the myelin and axonal membrane forming dimers or molecular zippers ([@bib1170], [@bib1515]). Whether lipids, glycolipids and phospholipids play also a role as auto-antigens in EAE and MS is not clear, although several evidences from experimental and clinical studies support such a role ([@bib1345]). Candiate myelin lipid auto-antigens in MS and/or EAE are shown in [Table 1](#tbl0005){ref-type="table"}. In a lipid microarray study of [@bib0740] co-immunization with sulfatides and co-application of sulfatide-specific antibodies worsened the clinical course of PLP~139--151~--EAE in SJL/J mice, and [@bib1385] found auto-antibodies to lipids such as oxidized cholesterol derivatives in the serum of MS patients with the immunopathologic pattern II according to [@bib0990]. However, the oxidized cholesterol derivatives did not affect the specific humoral and T cell response in MOG~55--75~--EAE.Table 1Putative protein and lipid auto-antigens in EAE and/or MS.AntigensResults in MS and/or EAEReferencesMyelin basic proteinT and B cell response in EAE and MS[@bib0340], [@bib0855]MOGT and B cell response in EAE and MS[@bib0890]PLPT and B cell response in EAE and MS[@bib1630]2*′*,3*′-*CNPT and B cell response in EAE and MS[@bib1045]NF 155Antibodies recognize the extracellular domain in MS and cause axonal injury in EAE, but only in preexisting demyelinated lesions[@bib0225], [@bib0300], [@bib1060]NF 186Antibodies recognize the extracellular domain in MS, inhibit axonal conduction in a complement-dependent manner and cause axonal injury in EAE[@bib0300], [@bib0590], [@bib1060]Neurofilament-MNeurofilament-M-specific T cells induce severe clinical EAE with confluent demyelination and massive axonal loss[@bib0850]Contactin-2/TAG-1Contactin-2/TAG-1-specific T cells induce inflammatory lesions in the cortex and white and gray matter thereby opening locally the BBB and causing occasionally clinical EAE[@bib0295], [@bib0300], [@bib1170], [@bib1515]S100βStrong T cell response in EAE[@bib0825]PhosphatidylserinePromotion of demyelination in marmoset EAE[@bib1240]SulfatidesT and B cell response in EAE[@bib0740]Oxidized phosphatidylcholineStrong antibody reactivity in MS brain and EAE spinal cord[@bib1375]Ganglioside GM1, sulfatide and galactosylceramideIncreased reactivity of pro-inflammatory cytokine secreting CD8^+^ T cells in MS patients[@bib1510]Gangliosides GM3 and GQ1bIncreased T cell response in primary progressive MS patients[@bib1315]Ganglioside GD1aIncreased antibodies in serum and cerebrospinal fluid of patients with MS and optic neuritis[@bib1050]Lactosylceramide and [l]{.smallcaps}-α-lysophosphatidylserineStrong antibody reactivity in serum and cerebrospinal fluid of MS patients[@bib0740], [@bib1385]Fig. 2Putative auto-antigens in EAE with indication of their preferential localisation. Insets refer to the ODC membrane (inset 1), myelin surface zone (inset 2), compact myelin zone (inset 3), myelin/axon interface zone (inset 4), and nodal and paranodal zone of node of Ranvier (inset 5). *Abbreviations*: CNP, 2′,3′-cyclic nucleotide-3′-phosphodiesterase; cyt, cytoplasm; ext, extracellular space; MAG, myelin-associated glycoprotein; MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein; NF, neurofascin; PLP, proteolipid protein; TAG, transient axonal glycoprotein.

Several studies have shown that actively induced EAE models can reproduce the typical temporal maturation of MS lesions from inflammation with or without deposition of immunoglobulin through demyelination and axonal damage to gliosis and partial remyelination. However, special phenotypes of MS pathology such as primary neuronal degeneration, shift of CD4^+^ T helper cells to CD8^+^ cytotoxic T cells and lesions in cortical areas are rarely reproduced by actively induced EAE models ([@bib0040], [@bib0490], [@bib0610], [@bib0925], [@bib1360]). Hitherto it is not clear to which extent cortical lesions account for the brain atrophy in MS. [@bib1100] could induce focal demyelinating lesions in the cortex of MOG--EAE rats by stereotactical injection of the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ). Corresponding to findings in MS the focal cortical lesions were rapidly remyelinated. Accordingly, in marmoset MOG--EAE focal cortical lesions were not the major cause of diffuse cortical atrophy ([@bib1365]). The potential pathomechanisms of CNS atrophy in MS are complex and may include several mechanisms of neuronal damage such as anterograde Wallerian degeneration, neuronal dying-back and neuronal soma and dendritic shrinkage ([@bib0330], [@bib1520]). Currently, disclosure of the exact mechanisms of axon damage is a major challenge of MS research, since it appears to be the main cause of clinical disability and may be the result of immune and/or non-immune attacks on neurons rather than a consequence of immune-mediated demyelination ([@bib1520]).

Concerning the aetiopathogenesis of MS the role of infections is still a matter of controversy. In mice lymphocytic choriomenigitis virus protein expression could elicit chronic autoimmune inflammation and demyelination in the CNS ([@bib0375]). A *Chlamydia pneumonia*-specific peptide sharing an immunodominant epitope with MBP-induced severe clinical and histological EAE ([@bib0905]), whereas intestinal parasites conveyed resistance to EAE in EAE-susceptible Lewis rats ([@bib1785]). Also, human herpes virus type 6, Epstein--Barr virus, measles virus and retroviruses have been implicated in the aetiopathogenesis of MS, but currently available experimental and clinical data are not convincing enough to justify anti-viral or antibiotic therapy in MS. However, experimental demyelinating diseases induced by Theiler\'s virus ([@bib1610], [@bib1635]), coronavirus ([@bib0880]) or canine distemper virus ([@bib1495]) are suitable models for the investigation of some aspects of MS pathology.

Milestones of the development of increasingly specific EAE models were ([Fig. 1](#fig0005){ref-type="fig"}):(i)Induction of EAE by transfer of total lymph node cells ([@bib1300]), isolated MBP-specific T cell-line cells ([@bib0100]) or interleukin-23 (IL-23)-dependent PLP-specific CD4^+^ T helper IL-17 (Th17) cells ([@bib0875]) into naive rats or mice, respectively, establishing distinct forms of adoptive transfer EAE (AT-EAE) and(ii)generation of transgenic mice with deletion (knock-out leading to loss-of-function) or over-expression (knock-in leading to gain of function) of pathogenetically relevant genes (reviewed in [@bib0845]). Examples of such genes are those encoding T cell receptors (TCRs) ([@bib0105], [@bib0515], [@bib0860], [@bib1095]), major histocompatibility complex (MHC) molecules ([@bib0440], [@bib0795], [@bib0925], [@bib1020]), cytokines (reviewed in [@bib0195], [@bib1260]) as well as neurotrophic factors ([@bib0925], [@bib0930], [@bib0950], [@bib1135]) and their receptors ([@bib0280], [@bib0950]).

The constitutive knock-out or knock-in of cytokine genes throughout the whole development and adulthood of an animal implies serious drawbacks due to redundancy and feed-back loops of cytokine signal pathways ([@bib1260], [@bib1560]). This constraint can been overcome by approaches with inducible spatially and temporally restricted gene targeting, which has been only recently introduced for studies directed to the CNS ([@bib0470], [@bib0645]).

Despite the obvious importance of autoimmune processes in the pathogenesis of MS, there is evidence for a non-immune origin of at least some subtypes of MS. For example, even aggressive immunosuppression is not sufficient to treat progressive MS. Therefore, additional experimental models are needed, especially for the study of non-immune-mediated demyelination and axonal loss via ODC degeneration. For this purpose a toxic model of demyelination has been developed that is based on the selective toxicity for ODCs of the copper chelator biscyclohexanone oxaldihydrazone (cuprizone) ([@bib0140], [@bib0205]). If young mice are fed with cuprizone, focal demyelination occurs predominantly in the cerebellar cortex and peduncle. After withdrawal of the toxin spontaneous remyelination can be seen predominantly in the rostral regions ([@bib1535], [@bib1620]). Thereby the cuprizone-model correlates well with histopathological features of MS, especially in the subtype or variant classified as histological pattern III according to [@bib0990], which renders it a useful tool for MS research ([@bib0350], [@bib0810]). Paradoxically, according to a recent report of [@bib0605] cuprizone ameliorates Theiler\'s murine encephalomyelitis suggesting that it might have immunomodulatory and/or anti-viral properties in addition to its toxic effects.

1.3. Current EAE models {#sec0020}
-----------------------

Currently, the most common mode of EAE induction is based on the injection of an encephalitogenic peptide, mostly MOG~35--55~ or PLP~139--151~, which is emulsified in CFA containing mineral oil and *Mycobacterium tuberculosis* strain H37RA, followed by intraperitoneal injections of pertussis toxin ([Fig. 3](#fig0015){ref-type="fig"} ). The resulting phenotype depends mainly on the antigen source and the genetic background of the animal species and strains used. For example, PLP~139--151~ induces a relapsing--remitting EAE in SJL mice, whereas MOG~35--55~ triggers chronic-progressive EAE in C57BL mice that are the most favored mice for transgenic experiments ([@bib0490]). Crossing of C57BL mice, which over-express MOG-TCR and MOG-specific B cells, resulted in a severe form of EAE that closely replicated Devic\'s variant of MS with inflammatory lesions of optic nerves and spinal cord ([@bib0105]). MOG-TCR transgenic mice backcrossed to SJL/J background develop a relapsing--remitting form of EAE with episodes altering between optic nerve, cerebellum and spinal cord. Evolution of this model depends on an intact B cell compartment. Apparently, MOG-TCR transgenic T cells expand endogenous auto-reactive B cells that manufacture pathogenic demyelinating auto-antibodies to a conformational epitope on native MOG protein whilst not recognizing the T cell target MOG peptide ([@bib1350]). The authors claim to have generated the first spontaneous animal model for relapsing--remitting MS. Current types of AT-EAE include those induced by Th17 cells suggesting that these newly detected effector cells may in part be responsible for the pathological heterogeneity of MS lesions ([@bib0005], [@bib0495], [@bib0620], [@bib0625], [@bib0695], [@bib0835], [@bib1380], [@bib1395]). All EAE models are directly accessible to investigation of the immune and nervous system ([Fig. 3](#fig0015){ref-type="fig"}), which interact during the pathogenesis of the disease and which are both targeted by established and experimental therapies.Fig. 3Most common animal models of MS with indication of the compartments investigated for analysis of systemic and local disease processes. For active immunization antigens are preferentially applied to the flank or toe pad of the animal, since draining lymph nodes of these areas mediate a highly effective systemic immune response to the putative auto-antigens as a first step for induction of autoimmune processes in the CNS. *Abbreviations*: AT-EAE, adoptive transfer EAE; CFA, complete Freund\'s adjuvant; i.p., intraperitoneal; i.v., intravenous; LN, lymph node; MOG, myelin oligodendrocyte glycoprotein; PB, peripheral blood; PLP, proteolipid protein; s.c., subcutaneous; SP, spleen, Th1 cells, T helper type 1 cells.

2. Investigation of immunogenetic and pathogenetic features {#sec0025}
===========================================================

2.1. Immunogenetics of EAE and MS {#sec0030}
---------------------------------

Since MS appears to be a polygenetically determined disease, efforts have been undertaken by linkage and association studies to define chromosomal regions, quantitative trait loci (QTL), that control the susceptibility to the disease and to compare these QTL with the susceptibility loci in the animal model EAE ([@bib1505]). The high frequency of intergenomic EAE/MS consensus genes supports the value of EAE for studying of MS features. Backcross (offspring-parent mating) and intercross (sibling mating) experiments with EAE susceptible and resistant animal strains of mice, rats, guinea pigs and hamsters revealed mainly MHC-linked QTL ([@bib0360], [@bib1250]). Combined-cross analysis could enhance the detection of QTL with moderate effects in rats ([@bib0705]). Genotyping of 150 microsatellite markers in F2 intercross populations of EAE-susceptible SJL/L mice and EAE-resistant C57BL/10.S mice identified QTL linked to increased latency of cortical motor evoked potentials in non-immunized animals, which correlated with earlier onset of the disease ([@bib1070]). This finding points to a role of myelin composition and synaptic transmission in susceptibility to EAE and provides a chance to detect individuals with high risk for autoimmune demyelination by QTL analysis before the disease is manifested. In MS, some immune response-related genes have been identified by genome-wide association studies using single nucleotide polymorphism analysis with microarray technique as being heritable risk factors of the disease, although their individual contribution is clearly modest with odds ratios for most not exceeding 1.2 ([@bib0685]). These genes include the interleukin (IL)-2α and IL-7α receptor genes on chromosomes 10 and 5, respectively, and some human leukocyte antigens (HLA) belonging to MHC class II molecules on chromosome 6 ([Table 2](#tbl0010){ref-type="table"} ) ([@bib0525], [@bib0685]). More recently, the genes encoding the following proteins have been confirmed as novel MS risk genes (explanation of abbreviations in [Table 2](#tbl0010){ref-type="table"}) ([@bib0055], [@bib0275], [@bib0285], [@bib0290], [@bib0540], [@bib0635], [@bib0640], [@bib0685], [@bib0715], [@bib1105], [@bib1445], [@bib1470]):-EV15, CD58, KIF1B, RGS1 and RPL5 (on chromosome 1),-IL-12A (on chromosome 3),-PTGER4 (on chromosome 5),-OLIG3-TNFAIP3 (on chromosome 6),-CD6 (on chromosome 11),-TNFRSF1A (on chromosome 12),-IRF8 and CLEC16A (on chromosome 16),-CD226 (on chromosome 18), and-TYK2 (on chromosome 19). Table 2Susceptibility genes of MS.GeneFunctionReferencesHLA-DRB1\*1501Antigen presentation[@bib0065], [@bib0220], [@bib0685], [@bib0795]IL-2α receptorT and B cell activation[@bib0685]IL-7α receptorT cell survival, differentiation and homeostasis, B cell development[@bib0525], [@bib0685]EV15GTPase activation[@bib0275], [@bib0635]CD58 (lymphocyte-associated antigen 3, LFA-3)Ligand of CD2, costimulatory molecule for T cells enhancing FoxP3 expression in Treg cells[@bib0285], [@bib0640]CLEC16A (C-type lectin domain family 16, member A)Unknown function, but highly expressed in dendritic cells, B cells and NK cells...[@bib0640], [@bib0715], [@bib1445]CD6Bacterial molecular pattern recognition and suppressing TNF-α, IL-6 and IL-1β[@bib0290], [@bib1470]IRF8 (IFN regulatory factor 8)Activation or repressing of IFN type I transcription[@bib0290], [@bib0715]TNFRSF1A (tumor necrosis factor receptor superfamily, member 1A)Pro-inflammatory and proapoptotic activity[@bib0290]OLIG3-TNFAIP3 (oligodendrocyte transcription factor 3---NF-α-induced protein 3)Development of neuronal cells, tumor suppression and anti-inflammation[@bib0290]IL-12A (IL-12p35)Growth factor for activated T and NK cells, enhancing the lytic activity of NK/lymphokine-activated killer cells[@bib1445]PTGER4 (prostaglandin E receptor 4)Activation of T cell factor signaling[@bib0290]RGS1 (regulator of G-protein signaling 1)B cell activation[@bib0715]TYK-2 (tyrosine kinase 2)Intracellular signal transduction of type I IFNs[@bib0715], [@bib1105]CD226Intercellular adhesion, lymphocyte signaling, cytotoxicity and lymphokine secretion mediated by cytotoxic T cells and NK cells[@bib0540]KIF1B (kinesin family member 1B)Motor protein transporting mitochondria and synaptic vesicle precursors[@bib0055]RPL5 (ribosomal protein L5)Transport of nonribosome-associated cytoplasmic 5S rRNA to the nucleolus for assembly into ribosomes.[@bib1445]

The strongest association to MS susceptibility, although not to the age of onset and severity of the disease, was found for the HLA-DRB1\*1501 allel ([@bib0065], [@bib0220]), whereas transgenic mice over-expressing the human HLA-DRB1\*1502 allel developed a severe MOG--EAE ([@bib0795]). In contrast, genes related to antigen processing can also slow down disease progression as reflected by a milder course of the disease in MOG~35--55~--EAE of congenic NOR/LtJ mice compared to the wild-type NOD mice ([@bib1065]). Similarly, congenic mapping of the rat genome confirmed that a chromosomal region homologous to a human MS susceptibility region confers protection against MOG--EAE ([@bib0700]). Also, transgenic MOG~35--55~--EAE mice over-expressing the TCR for MOG~35--55~ showed protective rather than pathogenic effects ([@bib1095]). In contrast, transgenic mice over-expressing MBP-specific TCR developed high frequency spontaneous EAE ([@bib0515], [@bib0860]). The relevance of these findings for the human disease remains to be elucidated. Research in EAE also yielded hints for the existence of chromosomal loci that control disease susceptibility in dependence of age and season pointing to a role of chronobiology in autoimmunity ([@bib1605]). Moreover, EAE susceptibility can vary even between different colonies of the same animal strain as demonstrated for Lewis rats purchased from different animal facilities ([@bib0510]). Since the genetic background of these animals is almost identical, other mechanisms, preferentially those involving gene regulating, may be responsible for differences in disease susceptibility and progression. Transcriptome and proteome analyses are powerful new tools for the elucidation of those mechanisms ([@bib0355], [@bib0395], [@bib0485], [@bib0670], [@bib0675]).

2.2. Gene expression studies by microarray analysis {#sec0035}
---------------------------------------------------

An integrated analysis of available data from genome-wide genetic screens and high-throughput gene expression studies in MS and EAE revealed that differentially expressed genes appear mainly in clusters rather than in uniform distribution throughout the genome ([@bib0395]). The hereby included hypothesis-neutral gene expression studies are mainly performed with microarray technique (RNA profiling) and applied in MS patients to peripheral blood mononuclear cells or brain tissue and in EAE animals to lymphatic and nervous tissue ([@bib0485], [@bib1595]). They deliver an increasing wealth of data, which implies a great challenge for bioinformatic analysis that may include pathway analyses using background information from the Gene Ontology project and other data bases as well as data mining approaches. Results of gene expression studies are generally hampered by methodical problems such as the heterogeneity of the material from different individuals and the difficulties in defining a reasonable threshold for differentially expressed genes. Nevertheless, meaningful data have already been obtained from expression studies in EAE that point to new EAE-QTL and susceptibility genes, dissect new pathogenic and protective pathways and identify new therapeutic targets ([@bib0245], [@bib0710], [@bib1055], [@bib1070], [@bib1145], [@bib1155], [@bib1270]). As an example, the comparison of the EAE-resistant strain C57BL/10.S with the EAE-susceptible strain C57BL/6 in the MOG~35--55~--EAE model strongly supported EAE-resistance to be an active process revealing new target genes for therapeutic intervention ([@bib1150]). Moreover, data of [@bib0070] derived from the MOG~35--55~--EAE model led to new conclusions such as(i)early non-specific BBB impairment (mainly neutrophil-related) secondary to immunization with CFA,(ii)transition from innate to adaptive immune responses before onset of EAE,(iii)identification of at least 3 discrete EAE phases (early EAE, peak EAE and early recovery) with characteristic gene expression patterns, and(iv)early neuronal damage.

Therefore, gene expression studies can provide new insights into the dynamics of discrete early and progressive phases of EAE on the transcriptional level, which are consistent with the histological and clinical phenotype. They can serve as a tool for fingerprinting of individual disease processes in man. As a practical consequence new therapeutic targets surface. RNA profiling has also enabled researchers to identify genes which support maintenance of the hematopoietic stem cell niche synapse as a source for therapeutic mesenchymal stem cells that can ameliorate EAE ([@bib1310]). On the other hand, EAE can also serve as a tool to validate new targets derived from gene-microarray analysis ([@bib0980]).

Despite the clear benefit of the transcriptome approach there are voices advising caution concerning overinterpretation of results of global gene expression analysis. In any case, due to its obvious limitations transcriptomics should be employed only with a clear and specific question in mind and carefully in view of the regulatory settings and potential pitfalls of the technique ([@bib0210], [@bib0390]). The same is true for the proteome approach (reviewed in [@bib0355], [@bib0945]). In EAE, it has served to generate differential protein expression profiles ([@bib0325], [@bib0965]), to monitor the diversity of autoantibody responses ([@bib1425]) and to validate new therapeutic targets derived from laser-capture micro-dissections of MS lesions ([@bib0545]). Also putative lipid auto-antigens could be identified by the microarray approach in MS and EAE ([@bib0740], [@bib1385]).

2.3. Immunopathogenesis {#sec0040}
-----------------------

There is still consensus amongst most researchers that immunological processes play a pivotal role in the pathogenesis and progression of MS ([@bib0490], [@bib0940], [@bib1565], [@bib1680]), although the aetiological factors may vary between different subtypes of MS and may not primarily affect the immune system, especially in cases with the histopathologic patterns III and IV according to [@bib0990]. Moreover, in early MS with histologic patterns I--III Wallerian degeneration seems to contribute significantly to axonal loss in the plaques and periplaque white matter ([@bib0330]). The current concept of pathogenetic processes in MS is schematically depicted in [Fig. 4](#fig0020){ref-type="fig"} , which indicates also therapeutic interventions and their putative targets. Recent paradigm shifts relate to the recognition of new roles for CD8^+^ T cells ([@bib0445]), B cells ([@bib0420]), innate immunity ([@bib1680]) and emerging pathogenic pathways causing neuronal damage ([@bib0045], [@bib0215], [@bib0330], [@bib0615]).Fig. 4Putative pathogenic mechanisms of MS. Auto-reactive lymphocytes may be recruited from peripheral lymphoid organs and after migration through the BBB reactivated in the CNS, where an inflammatory cascade is initiated leading to subsequent damage of myelin and axons. Alternatively, primary oligodendroglial and axonal degeneration may be followed by an inflammatory autoimmune process. The adjacent table depicts the putative pathogenic processes that are targeted by established and experimental therapies. Treatments are grouped according to the contribution made by EAE to their development, i.e. they are either successfully translated into the clinic (green), only successful in EAE (red) or currently tested in EAE and/or MS (yellow). *Abbreviations*: AICAR, 5-aminoimidazole-4-carboxamide-1-β-[d]{.smallcaps}-ribofuranoside; APC, antigen-presenting cell; APL, altered peptide ligand; BBB, blood--brain barrier; BDNF, brain-derived neurotrophic factor; CD, cluster of differentiation; CNS, central nervous system; CNTF, ciliary neurotrophic factor; CRYAB, αB-crystallin; CYLA, Calpain inhibitor; 3,4-DAA, N-(3,4,-dimethoxycinnamoyl) anthranilic acid; DRD1, dopamine receptor type 1; EGCG, (−)-epigallocatechin-3-gallate; IL, interleukin; IFN-γ, interferon-γ; major histocompatibility complex; MOG, myelin oligodendrocyte glycoprotein; MP, methylprednisolone; MRI, magnetic resonance imaging; NK, natural killer; ODC; oligodendrocyte; PLP, proteolipid protein; PPAR-α, peroxisome proliferator-activated receptor-α; SSRI, selective serotonin reuptake inhibitor; Tc, cytotoxic T cell; TCR, T cell receptor; TGF-β, transforming growth factor-β; Th cell, helper T cell; TNF-α, tumor necrosis factor-α.

EAE models have considerably contributed to our understanding of immune regulatory processes in the pathogenesis of MS ([@bib0490], [@bib1690]). While traditionally regulatory (suppressive) activity in autoimmune processes was primarily attributed to CD8^+^ T cells ([@bib1790]), more recently CD4^+^CD25^+^FoxP3^+^ regulatory T cells ([@bib1740]) have attracted interest in this respect ([@bib0365], [@bib1280], [@bib1615]). They seem to be important as antagonists of CD4^+^ Th17 cells ([@bib0005], [@bib0960], [@bib1380]) that are supposed to be effector cells in EAE ([@bib0620], [@bib0660], [@bib0970], [@bib1570]) and MS ([@bib0495]). However, the pathogenic role of Th17 cells and of IL-17 in EAE is controversial. According to findings of [@bib0530] in transgenic mice the *in vivo* function of IL-17 in the CNS may be redundant and the members of the IL-17 family IL-17A and IL-17F may contribute only marginally to the autoimmune pathogenesis of MOG~35--55~--EAE. On the other hand, [@bib0660] found that IL-17A promotes breakdown of the BBB, a crucial step in the development of EAE. Moreover, findings of [@bib1230] point to a pro-inflammatory role of the Th17-derived IL-9 in MOG~35--55~--EAE. Th17 cells are driven by IL-21 ([@bib0835]) and IL-23 ([@bib0875], [@bib1080]) and suppressed by IL-27 ([@bib0400], [@bib1665]). Recently, the IL-7-IL-7R pathway has been implicated in the survival and expansion of effector/memory Th17 cells. Blockade of IL-7R rendered differentiated Th17 cells susceptible to apoptosis which led to attenuation of MOG--EAE ([@bib0970]). Corresponding IL-17^+^ CD8^+^ Tc cells show impaired cytotoxicity and IFN-γ production, but may through their excessive IL-17 production contribute to inflammatory processes in EAE and MS ([@bib0650]). Recently, [@bib1545] could demonstrate in brain slices of transgenic mice that myelin-directed CD8^+^ Tc cells cause extensive damage not only of the myelin sheath, but also of the axons. Consequently, these cells may contribute to axonal loss in EAE and probably also in MS with the immunopathologic pattern I according to [@bib0990].

B cells are involved in the immunopathogenesis of MS and EAE at least by two functional activities, i.e. as antigen-presenting cells (APCs) and as antibody producers ([@bib0420], [@bib0520], [@bib0630], [@bib1035], [@bib1680], [@bib1780]). In addition they may co-stimulate T cells, facilitate recruitment of inflammatory cells to the CNS and myelin opsonization, but also promote remyelination, and take part in immunoregulatory processes. Anti-myelin antibodies are supposed to be major components of the histopathologic MS pattern II according to [@bib0990]. A special role as targets for antibodies in distinct types of EAE and MS is ascribed to the myelin molecules MOG ([@bib0535]) and the axonal molecule neurofascin ([@bib0630]).

Another distinct lymphocyte subpopulation that has been implicated in CNS autoimmunity is the γδ^+^ T cell subset bearing TCRγδ. These fetal-type T cells are increased in number in MS cerebrospinal fluid ([@bib1140]) and may exert pathogenic and regulatory functions (reviewed in [@bib0150] and [@bib0520]). Interestingly, the majority of IL-17 producing host cells in a Th1-mediated AT-EAE belonged to the γδ^+^ T cell type ([@bib0895]).

Adding to the complexity, there is an obvious pathogenic role for EAE and MS of innate immunity mediated by dendritic cells, monocytes and microglia ([@bib0455]). Whereas the adaptive immune system seems to drive mainly relapses of MS, abnormalities of the innate immune system may prevail in the progressive stage of the disease ([@bib1680]).

An important aspect of MS pathogenesis is the apoptotic activity in the lymphatic and nervous system. Therefore, apoptotic processes have been analysed in EAE. While apoptosis plays obviously a pivotal pathogenic role when affecting ODCs ([@bib0645]), it appears to be protective when eliminating myelin-reactive and bystander T cells ([@bib1765]). This process is augmented by therapeutic drugs such as methylprednisolone (MP) ([@bib1480]) and resveratrol ([@bib1525]).

The role of cytokines and neurotrophic factors for the pathogenesis of MS and EAE has been investigated in a plethora of studies and the results have been reviewed elsewhere ([@bib0520], [@bib0680], [@bib0920], [@bib0950], [@bib1135], [@bib1260], [@bib1265]). For details the reader is referred to these reviews.

In addition to the mentioned immunopathogenic pathways a direct crosstalk between the immune and nervous system may influence the pathogenesis of MS and EAE ([@bib0790], [@bib1160]). This involves direct effects of cytokines and chemokines on nerve cells and modulation of immune cell activity by neurotrophins and neurotransmitters implicating new treatment approaches, e.g. by associative conditioning ([@bib0725]). Disclosure of the complex mechanisms of neuro-immune interactions requires further investigations in the EAE model.

Many other aspects of MS research are investigated in the animal model. Among them monitoring of disease activity by traditional magnetic resonance imaging (MRI) ([@bib1180]) and new bioluminescence techniques ([@bib1000]) deserve special attention. Identification of reliable surrogate markers for diagnostic and prognostic purposes (responder detection for specific therapies, disease follow-up) will be a prominent task of the future. However, a consistent limitation for the translation of experimental results into the clinic is the different situation in EAE and MS concerning the timeline of detection of clinical signs and of therapeutic interventions ([Fig. 5](#fig0025){ref-type="fig"} ). Whereas in EAE pathological processes can be observed from the beginning and treatment approaches can be started at the early pre-clinical phase, in MS diagnostic measures will commonly not be initiated before first clinical signs are present and the intensity of treatment increases usually until late progression of the disease.Fig. 5Timeline of the pathophysiological and clinical course of EAE and MS. In EAE, the complete pathological course including the pre-clinical phase is detected and immune therapeutic interventions start early and decrease usually with the proceeding time. In MS, there is an opposite situation. First radiological signs remain usually undetected and immunomodulatory treatment starts only with first clinical signs and is usually intensified until late progression of the disease. *Abbreviations*: CIS, clinical isolated syndrome; CNS, central nervous system; RIS, radiologic isolated syndrome; RRMS, relapsing--remitting MS; SPMS, secondary progressive MS.

3. Development and validation of novel therapies {#sec0045}
================================================

3.1. Therapies developed primarily in EAE {#sec0050}
-----------------------------------------

Despite extensive screening for new targets of MS therapy in EAE so far only a few of the established MS therapies have been developed in the animal model. Examples are glatiramer acetate, mitoxantrone and natalizumab ([@bib0800], [@bib1565]).

The glatiramer acetate preparation is a random polymer consisting of repeated sequences of the four amino acids glutamic acid, lysine, alanine and tyrosine that occur in MBP in a specific molar ratio. It was primarily called copolymer 1 and tested first for its encephalitogenic potency and subsequently for its influence on guinea pig EAE ([@bib1600]). Surprisingly, it turned out that copolymer 1 suppressed rather than induced EAE, most probably via stimulation of Th2/Th3-mediated anti-MBP immune response ([@bib0015], [@bib0020]). Recent studies utilising sophisticated immunologic techniques point to a more complex mechanism of action of glatiramer acetate, including modification and killing of APCs, generation of regulatory T cells and turning the polyclonal CD8^+^ T cell response into an oligoclonal one ([@bib1390]).

Mitoxantrone has first been proven to be a powerful immunosuppressive drug in EAE ([@bib1405]) and it is now a second-line component of escalating MS therapy ([@bib0550], [@bib0840], [@bib1205], [@bib1210], [@bib1415]). Its mechanism of action relies most probably on cytotoxic effects on lymphocytes and induction of apoptosis of APC such as monocytes and dendritic cells ([@bib1200], [@bib1655]).

Natalizumab is a monoclonal antibody (mAb) that inhibits the transmigration of immune cells into the inflamed parenchyma of lymphatic organs and the CNS. It binds to α4β1-integrin (CD49dCD29, very late activation antigen-4) on lymphocytes and blocks the interaction with the integrin ligand CD106 (vascular cell adhesion molecule-1) on endothelia cells thereby being effective in preventing EAE ([@bib1400], [@bib1735]). It is the first mAb approved for therapeutic trials in MS ([@bib1355]) now belonging to second-line MS therapeutics, although it carries the risk to activate the polyoma virus JC leading to progressive multifocal leukoencephalopathy, especially if applied in combination with IFN-β ([@bib0230], [@bib0815], [@bib0870], [@bib1590], [@bib1745]). Recently, even cases of progressive multifocal leukoencephalopathy on natalizumab monotherapy have been reported ([@bib0230], [@bib0560], [@bib0565], [@bib0915], [@bib1695]).

3.2. Therapies investigated secondarily in EAE {#sec0055}
----------------------------------------------

A number of established MS therapies have subsequently been investigated in the EAE model. The aims are:(i)to get a deeper insight into the mechanisms of action including disclosure of the specific targets of the therapies and(ii)to improve regimens of old therapies and to develop new therapies targeting the same pathogenic mechanisms, but being more convenient for clinical practice (low frequency of application, oral application) and avoiding adverse side-effects.

For example, with respect to methylprednisolone therapy for MS relapses [@bib1480] could unravel a switch from cytoplasmic to nuclear effects accompanied by enhanced T cell apoptosis with increasing steroid dosage. Moreover, liposome encapsulated MP revealed a dose-dependently increased therapeutic efficiency compared to free MP in EAE ([@bib0935]). In IFN-β treated EAE, interruption of therapy caused disease exacerbation ([@bib1640]). In an attempt to explore the influence of intravenous immunoglobulin (IVIg) therapy on the local immune response in the CNS, [@bib0730] found accumulation of IVIg only in active CNS lesions with BBB breakdown limiting its prospects for repair processes. However, natural CD4^+^CD25^+^FoxP3^+^ regulatory T cells were enhanced by prophylactic application of IVIg in an EAE study of [@bib0365] suggesting a potential benefit of this therapy in early onset MS.

In other therapeutic trials, two treatments have been combined in order to achieve synergistic effects and/or to reduce adverse side-effects of single agents. For example, combined application of MP and erythropoietin protected neurons and axons of retinal ganglion cells and optic nerve of rats with MOG-induced EAE from morphological and functional impairment, whereas monotherapy caused only isolated neuronal or axonal protection without clinical benefit ([@bib0305]). In a MBP-induced active rat EAE model, the anti-inflammatory, anti-demyelinating and neuroprotective effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitory statins could be improved by combination with the selective phosphodiesterase-4 inhibitor rolipram ([@bib1280], [@bib1285]) or the protein kinase A activating substance 5-aminoimidazole-4-carboxamide-1-β-[d]{.smallcaps}-ribofuranoside ([@bib1275]), even when the statin was applied in suboptimal doses. For rolipram alone, beneficial effects in the animal model could previously not be reproduced in the human system ([@bib1775]). In actively induced chronic murine EAE a synergistic therapeutic effect of IFN-β and the immunomodulatory drug laquinimod was observed ([@bib1455]). In a patient study, the IFN-β-mediated up-regulation of the anti-inflammatory cytokine IL-10 was enhanced by additive administration of the non-selective phosphodiesterase inhibitor pentoxiphylline ([@bib1670]). Pentoxiphylline also reduced side-effects of IFN-β therapy such as myalgia, fever and injection site reactions ([@bib1410]). IVIg decreased T cell apoptosis and liver damage, but increased ODC apoptosis in high-dose MBP-treated rats with AT-EAE induced by MBP-specific T cells ([@bib1685]). But there are also perilous combination effects, which cannot always be foreseen and thereby prevented in the animal model as illustrated by the hazardous combination of IFN-β with natalizumab ([@bib0565], [@bib0815], [@bib0870], [@bib1590]) or statin ([@bib0130]).

While disease-modifying agents act largely through modulation of peripheral immune mechanisms, some of them appear to act additionally or even predominantly locally within the CNS, e.g. at the BBB like IFN-β ([@bib0320]) and natalizumab ([@bib1400]), on resident auto-reactive T cells and ODC like fingolimod ([@bib1125], [@bib1130], [@bib1290]). When entering the CNS via a locally disrupted BBB at lesion site, IFN-β may also directly act on astrocytes ([@bib0160]) and microglia ([@bib1370]) and even exert direct protective effects on neurons ([@bib1335]).

3.3. Therapy failures in MS {#sec0060}
---------------------------

On the other hand, there are several examples of compounds which were quite effective in curtailing disease activity in the animal model but turned out to lack therapeutic utility or proved to generate inacceptable adverse effect in MS patients. These inconsistencies prompted [@bib1550] to consider EAE a "misleading model of MS". Examples for therapy failures in MS are given in [Table 3](#tbl0015){ref-type="table"} . Reasons for the discrepant result obtained in the animal and human systems could be manifold. Their nature may be genetic (species differences, peculiarities of inbred animal strains), pathogenetic (individual variability between MS patients) or kinetic (different ontogeny and biorhythms, temporal differences of immune reactivity and response to therapy). Additionally, in MS the BBB may be insufficiently disrupted as compared to EAE thereby preventing therapeutic molecules to reach their target within the CNS. This seems to be relevant especially when targeting cytokines in MS. For example, the mAb to IL-12 p40 ustekinumab failed to improve relapsing--remitting MS despite promising results in rodent and marmoset EAE ([@bib1500]; reviewed in [@bib1575]). Other promising therapeutic principles revealed already in the animal model limited benefit or adverse effects precluding their use as MS therapeutics. Examples are:(i)the neuroprotective polypeptide hormone ciliary neurotrophic factor (CNTF), which elicited an acute-phase response in rat liver ([@bib0315]),(ii)the anti-adhesion molecule mAb anti-CD54, which revealed no MRI effect in AT-EAE ([@bib1180]),(iii)the Na^+^-channel blocker phenytoin, which potentially protects demyelinated axons, but resulted in exacerbation of MOG--EAE after withdrawal ([@bib0135]),(iv)the phosphodiesterase-4 inhibitor rolipram, while very effective in suppressing EAE, failed to suppress inflammatory activity as gleaned through magnetic resonance imaging in a pilot trial in patients with relapsing--remitting MS ([@bib0120]),(v)the immunosuppressive drug cyclosporin A prevented BBB disruption and suppressed the development of EAE, but was classified as unacceptable for treatment of MS based on risk/benefit consideration due to low efficacy and frequent adverse reactions ([@bib0500], [@bib0745], [@bib0800], [@bib1075], [@bib1305]). Table 3Failure of translation of experimental therapies from the animal model to the clinical practice (selected examples).TherapyResults in MS patientsReferencesAnti-TNF-α mAb infliximabIncreased MRI activity[@bib1645]Anti-CD3 and anti-CD4 antibodiesNo significant clinical effect[@bib1700]Anti-CD28 mAb TGN-1412Cytokine storm causing multiple organ failure[@bib0655]Altered peptide ligandsAnaphylactic reactions and exacerbation of MS[@bib0115], [@bib0750]Oral tolerogensNo significant clinical effect[@bib0385]SulfasalazineOnly transient clinical effect[@bib1220]LinomideCardiopulmonary toxicity[@bib1225]The table is reproduced from [@bib1165] with permission of the publisher (Springer).

If one therefore considers only the therapeutic trials conducted in EAE and their translation into the clinic, it may well be regarded as a misleading model of MS. However, several aspects of the aetiopathogenesis of MS such as susceptibility genes, immunoregulatory circuits, mechanisms of immune cell activation, migration and elimination as well as of nervous tissue destruction and repair have been successfully studied in EAE rendering it a useful model of MS ([@bib0595], [@bib1485]). EAE will be of continued utility in the future if one capitalizes on the availability of distinct types of EAE, including those induced in transgenic and knockout animals, to explore pathogenic pathways and strategies of intervention in different subtypes or variants of MS.

4. Perspectives {#sec0065}
===============

As outlined before, several therapeutic interventions have been successful exclusively in EAE, but not in MS. Other therapeutic agents have shown proven benefit in both EAE and MS. A survey of these agents is given in [Table 4](#tbl0020){ref-type="table"} . There are also few instances where therapeutic agents for the treatment of MS have been clinically developed without prior evaluation in the animal model. Examples of such drugs including their proposed mechanism of action are listed in [Table 5](#tbl0025){ref-type="table"} .Table 4Therapeutic agents effective in both MS and EAE.AgentClinically isolated syndrome (CIS)MSEAEAzathioprine[@bib1760][@bib0145], [@bib1440]Cyclophosphamide[@bib0465], [@bib1215], [@bib1655][@bib1025]Fingolimod[@bib0240], [@bib0760][@bib0060], [@bib0410], [@bib1125], [@bib1130], [@bib1290]Fumarate[@bib0775][@bib1475], [@bib0775]Glatiramer acetate[@bib0265][@bib0255], [@bib0800][@bib0015], [@bib0020], [@bib1390], [@bib1600]IFN-β[@bib0250], [@bib0265], [@bib0690], [@bib0755], [@bib0770][@bib0765], [@bib0800], [@bib1030][@bib0320], [@bib1460]Laquinimod[@bib0260][@bib0175], [@bib1455], [@bib1675], [@bib1725]Methotrexate[@bib0505], [@bib1215], [@bib1655][@bib0865]Methylprednisolone[@bib0415][@bib0995]Mitoxantrone[@bib0335], [@bib0550], [@bib0840], [@bib1205], [@bib1210], [@bib1415], [@bib1655][@bib1405], [@bib1205]Natalizumab[@bib1355], [@bib1400][@bib1400], [@bib1735]Table 5Experimental therapies for MS evaluated in clinical trials without prior investigation in the animal model (selected examples).TherapyProposed mechanism of actionReferencesMonoclonal antibodies[@bib0125], [@bib1085], [@bib0940] - Rituximab,ocrelizumab, ofatumumabAnti-CD20 inhibits B cells.[@bib0580], [@bib0585] - DaclizumabAnti-CD25 inhibits lymphocyte activation and expands subpopulation of regulatory T cells.[@bib1430], [@bib1720] - AlemtuzumabAnti-CD52 depletes lymphocytes.[@bib0190], [@bib0720]TeriflunomideDihydro-orotate dehydrogenase inhibitor disrupts the immunologic synapse.[@bib1235], [@bib1770]TemsirolimusAntifungal antibiotic rapamycin acts immunosuppressive.[@bib0200], [@bib0785]Cladribine2-Chloro-2′-deoxyadenosine alters binding of transcription factors to the gene regulatory AT-rich sequences; accumulated cladribine nucleotides disrupt DNA synthesis and repair and suppress CD4^+^ and CD8^+^ T cells.[@bib0405], [@bib0480], [@bib0570], [@bib1530]The table is reproduced from [@bib1165] with slight modification with permission of the publisher (Springer).

Nonetheless, an increasing number of emerging therapies for MS are currently being tested in pre-clinical phases by making use of the EAE model ([@bib0235], [@bib0940], [@bib1680]). The most promising experimental therapies rely on gene transfer, stem cell transplantation, oral administration of small molecular weight disease-modifying drugs and intravenous or subcutaneous application of mAb targeting cells or molecules crucial in the pathogenesis of the disease ([@bib0045], [@bib0125], [@bib0180], [@bib0350], [@bib0580], [@bib0585], [@bib0595], [@bib0805], [@bib1340], [@bib1720]). [Table 6](#tbl0030){ref-type="table"} provides a survey of experimental therapeutic approaches that are currently being investigated, some of which being already approved for phase I-III clinical trials. [Table 6](#tbl0030){ref-type="table"} also includes proposed mechanisms of action of the new therapies. Putative targets of established and experimental MS therapies with and without prior testing in EAE are indicated in [Fig. 4](#fig0020){ref-type="fig"}. Other experimental approaches for MS are based on vaccination, e.g. with pathogenic T cells, TCRs, dendritic cells pulsed with antigen, DNA vaccine encoding MBP, axonal growth inhibitors associated with myelin or pro-inflammatory cytokines. These approaches are extensively reviewed elsewhere ([@bib0270]). Recently, a new therapeutic target for a more selective treatment of EAE and MS compared to available therapies has been proposed, i.e. the IL-7-IL-7R pathway that affects pathogenic Th17 cells, but spares regulatory T cells and unrelated immune cells ([@bib0970]).Table 6Experimental therapies for MS as tested in EAE.Therapeutic approachProposed mechanism of actionReferencesGene therapy[@bib0450] - IL-4Inhibits Th1 cell activation.[@bib0165], [@bib0180] - IFN-βInhibits local autoimmune reaction in the CNS.[@bib1010]Stem cell transplantation[@bib1490] - Mesenchymal stem cellsModulate T cell function, decrease IL-17 via IL-23 secretion.[@bib1310], [@bib1665] - Neural stem cellsDown-regulate inflammation, stimulate the endogenous brain repair system.[@bib0025], [@bib0345], [@bib0350], [@bib1040], [@bib1340]Neurotrophic factors[@bib1135] - BDNFReduces inflammation and apoptosis.[@bib1015] - ErythropoietinActivates the neuroprotective phosphatidylinositol 3-kinase/Akt pathway, down-regulates glial MHC class II.[@bib0010], [@bib1465], [@bib1755]Monoclonal antibodies[@bib0185], [@bib1005], [@bib1435]NatalizumabAnti-CD49d inhibits lymphocyte adhesion.[@bib1400], [@bib1590]Anti-cytokinesSmall molecular weight drug suppresses pro-inflammatory cytokines.[@bib0780]CRYABStress protein αB-crystallin has an anti-inflammatory effect.[@bib1255]Beta-lactam antibioticCeftriaxone modulates myelin antigen presentation and impairs antigen-specific T cell migration into the CNS.[@bib1090]SteroidsEstradiol and progesterone increase BDNF and myelination.[@bib0460]Statins3-Hydroxy-3-methylglutaryl-coenzymeA-reductase inhibitors prevent geranyl-geranylation of RhoA GTPase and its tethering to the membrane and thereby inhibit T cell activation and infiltration into the CNS.[@bib0030], [@bib1155], [@bib1555], [@bib1660], [@bib1750]Fingolimod (FTY720)Sphingosine-1-phosphate agonist reduces systemic T and B cell response as well as auto-reactive T cells in the CNS and it promotes remyelination by stimulation of ODC function.[@bib0060], [@bib0410], [@bib0760], [@bib1125], [@bib1130], [@bib1290]Fumarate (BG-12)Fumaric acid esters increase the anti-inflammatory cytokine IL-10.[@bib1475]MinocyclineInhibits matrix metalloproteinases and thereby T cell transmigration.[@bib0170]Gemfibrozile, fenofibrate, ciprofibraPeroxisome proliferator-activated receptor (PPAR)-α agonists increase the anti-inflammatory cytokine IL-4.[@bib0985]LaquinimodLinomide-derivative ABR-215062 changes the cytokine balance towards the anti-inflammatory cytokines IL-4, IL-10 and TGF-β[@bib0175], [@bib0260], [@bib1455], [@bib1675], [@bib1725]AICARProtein kinase A activating 5-aminoimidazole-4-carboxamide-1-β-[d]{.smallcaps}-ribofuranoside inhibits the pro-inflammatory cytokines IFN-γ and TNF-α and induces the anti-inflammatory cytokines IL-4 and IL-10.[@bib1195]CYLACalpain inhibitor reduces inflammatory infiltration, demyelination and axonal injury.[@bib0575]3,4-DAADerivative of tryptophan metabolite N-(3,4,-Dimethoxycinnamoyl) anthranilic acid inhibits pro-inflammatory cytokines.[@bib1330]EGCGGreen tea constituent (−)-epigallocatechin-3-gallate blocks proteasome complex, proliferation and TNF-α production of encephalitogenic T cells and formation of neurotoxic reactive oxygen species.[@bib0035]FlavonoidsLuteoline scavenges oxygen radicals, inhibits RhoA GTPase and prevents monocyte infiltration into the CNS.[@bib0600]Metallothionein I and IIAntioxidant proteins act anti-inflammatory and neuroprotective.[@bib0370]Vitamin D1,25-Dihydroxyvitamin D3 declines inducible nitric oxide synthase, chemokines and monocyte recruitment into the CNS and stimulates activated CD4^+^ T cell apoptosis in the CNS.[@bib1320]K^+^-channel blockerAlkoxypsoralens, kaliotoxin, charybdotoxin, psora-4, bupivacaine, anandamide, spermine and ruthenium red inhibit T cell activation.[@bib0095], [@bib1110], [@bib1580], [@bib1715]Na^+^-channel blockerPhenytoin, flecainide and lamotrigine prevent axonal degeneration.[@bib0085], [@bib0090], [@bib0975]Dopamine receptor antagonistsDRD1 antagonist SCH23390 blocks dopamine receptors on Th17 cells.[@bib1190]Glutamate receptor antagonistsAMPA/kainate antagonists NBQX and MPQX prevent glutamate-mediated demyelination and neuronal death.[@bib1540]Histamine receptor antagonistsHistamine-1 receptor antagonist hydroxyzine blocks mast cell degranulation.[@bib0310]Serotonin reuptake inhibitorsVenlafaxine suppresses pro-inflammatory cytokines.[@bib1650]Bifunctional hybrid moleculesBifunctional peptide inhibitor (BPI)Hybrid peptides made of integrin CD11a~237--246~ and antigenic epitopes PLP~139--151~ or glutamic acid decarboxylase GAD~208--217~ block the immunologic synapse.[@bib0820]Fulleren hybrid molecule (ABS-75)Hybrid molecules made of an antioxidant carboxy-fullerene moiety and NMDA receptor-targeting adamantyl groups inhibit oxidative injury, chemokine expression, CD11b^+^ cell infiltration, demyelination and axonal loss.[@bib0075]The table is reproduced from Mix et al. (2008) with slight modification with permission of the publisher (Springer).

An important field of therapeutic approaches in EAE and MS that will deserve more attention in the future is the enhancement of remyelination. So far experimental trials have involved transplantation of neural stem cells, ODC precursor cells, Schwann cells and olfactory ensheathing cells and application of growth factors such as platelet derived growth factor and epidermal growth factor ([@bib0425]). However, these trials are hampered by the fact that the demyelinating lesions are regularly wide-spread and dispersed within the CNS and that they, additionally, lack stimulating factors of ODC precursor cell recruitment and differentiation, or even contain inhibitory factors of remyelination like the neurite outgrowth inhibitor-A (Nogo-A) and its receptor component leucin-rich repeat and Ig domain containing-1 (Lingo-1) ([@bib1325]). Therefore, current efforts to enhance remyelination in EAE and MS rely mainly on established therapies with remyelinating potency such as IVIg, especially polyclonal IgM ([@bib0110], [@bib1625], [@bib1710]), glatiramer acetate ([@bib0020], [@bib0050], [@bib1390]) and fingolimod ([@bib1125], [@bib1130]) or on the application of antagonists of the remyelination inhibitors Nogo-A and Lingo-1 ([@bib0155], [@bib1115], [@bib1120], [@bib1450], [@bib1730]).

This review is restricted to the EAE model of MS and a short reference to the toxic cuprizone-mediated model of demyelination. Further information on advantages and disadvantages of EAE and additionally of virus-mediated demyelinating diseases can be derived from the excellent monograph "Experimental models of multiple sclerosis" edited by [@bib0885].

In summary, specific questions of MS genetics, pathogenesis and therapy require investigations in different available and forthcoming EAE models. A comparison of the most important immunopathological, clinical and therapeutic features of EAE and MS is given in [Table 7](#tbl0035){ref-type="table"} . Thereby it becomes obvious that great precaution is advisable when translating the results of experimental therapeutic trials into clinical practice.Table 7Comparison of immunopathological, clinical and therapeutic features of EAE and MS.EAEMSGeneticsSusceptible and resistant animal strains and colonies, e.g. C57BL/6 vs C57BL/10.S mice and different colonies of Lewis ratWeak evidence of association (confirmed only for HLA-DRB1\*15), risk alleles: IL-2RA, IL-7RA and EV15Pathology - InflammationDominant (CD4^+^ T cells and macrophages)Rare (type I/II, CD4^+^/CD8^+^ T cells, CD20^+^ B cells, macrophages) - DemyelinationRare (anti-MOG--EAE)Strong - DegenerationLate (murine EAE)Early (type III/IV) - Cortical lesionsRare (MOG--EAE in marmosets)RareClinical course - AcuteFrequent (active EAE)Rare (Marburg type) - Primary chronic-progrssiveRare (MOG--EAE, AT-EAE)Rare (\<10%) - Relapsing--remittingRare (PLP~139--151~--EAE, pertussis toxin-EAE)Frequent (\>90%)- Immunotherapy - Immunosuppression/immunomodulationAzathioprine, IFN-β, glatiramer acetate, gene therapy, stem cell transplantation, mitoxantrone, mAb, small molecular weight disease-modifying drugsAzathioprine, IFN-β, glatiramer acetate, plasma exchange, immunoadsorption, mitoxantrone, mAb, IVIg - Anti-inflammatoryMethylprednisoloneMethylprednisolone - Antigen specificAltered peptide ligands, bifunctional peptide inhibitors, oral and nasal tolerance, DNA vaccines - NeuroprotectiveCNTF, BDNF, erythropoietin
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